Plain-English translation of ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether two medications—sintilimab and bevacizumab biosimilar—can help prevent liver cancer from returning after surgery in patients whose tumors had ruptured and caused bleeding. These two medications work in different ways to help your immune system fight cancer cells and block the growth of new blood vessels that feed tumors. The trial will look at whether this combination is safe and how well it works in people recovering from emergency surgery.
After surgery to remove a ruptured liver tumor, many patients experience cancer recurrence, but there is currently no proven medication to prevent this. Recent research shows that this combination of medications has helped advanced liver cancer patients, so researchers want to test whether it can also help prevent recurrence in people after surgery.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the two medications every 3 weeks. Each infusion visit would involve receiving sintilimab (200 mg) and bevacizumab biosimilar (15 mg per kilogram of body weight) on the same day. You would need regular blood tests and imaging scans to monitor your health, check for side effects, and see if the cancer is staying away. The study involves 35 patients total, and you would be followed closely by the research team at Ruijin Hospital throughout your treatment.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China